Echec de Lirilumab en monothérapie - ACHAT - OC 17,5€ (vs 19,5€)
La biotech française a publié hier les résultats « top line » de Lirilumab en monothérapie dans la Leucémie Myéloïde Aiguë (LAM). Ces résultats sont négatifs avec un critère primaire d’efficacité : « survie sans leucémie » qui n’a pas été atteint. Suite à cet échec, qui ne nous semble pas remettre en cause le partenariat avec BMS, nous réduisons notre objectif de cours de 19,5€ à 17,5€ après le retrait de la valorisation de Lirilumab en monothérapie dans la LAM. Nous ne modifions pas notre thèse d’investissement et maintenons notre recommandation ACHAT.Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.